Ju Li1, Pengcheng Rao1, Dan Yang1, Tong Zhou1, Jianguo Gan1, Die Lv1, Shuting Zhou1, Yang Peng1, Xiaoqiang Xia1, Qianming Chen1, Yuchen Jiang1, Jian Jiang2, Xiaoping Xu1,*, Xiaodong Feng1,*
BIOCELL, Vol.50, No.5, 2026, DOI:10.32604/biocell.2026.075437
- 13 May 2026
Abstract Objective: Multiple programmed cell death (PCD) pathways have been individually reported to be triggered by cisplatin, but whether and how they are co-regulated remains unclear. In this study, we comprehensively investigate the spectrum of cisplatin-induced PCD. Methods: We employed integrated in vitro and in vivo models, including human cancer cell lines, a Cal27 xenograft mouse model, and paired clinical specimens from an oral squamous cell carcinoma patient receiving neoadjuvant cisplatin-based chemotherapy. A comprehensive methodological suite-encompassing cell death assays, Western blotting, Hematoxylin and eosin staining, immunofluorescence, Cyclic multiplexed tissue staining, and pathway-specific pharmacological inhibitors was utilized to dissect the… More >